Would you believe it if I said another day and another buyout with a large premium? I think the lack of M&A had been blamed for some of the previous years of underperforming for the sector and I believe that was a fair point. That is certainly not the case this year. While the sector […]
BELLUS Health – A Fresh Look at BLU-5937 in Refractory Chronic Cough as A Phase 2b Turnaround Play
We believe this is an opportune time to revisit BELLUS Health (BLU, BLU.TO), as their Phase 2b trial results are set to be released in Q3 (interim analysis) and Q4 (Top-Line results) this year. Recall, this is a clinical stage biopharma company based in Canada (Laval) and the US (Philadelphia), developing novel medicines for the […]
